IMUX
Price
$0.94
Change
-$0.04 (-4.08%)
Updated
Oct 6 closing price
Capitalization
92.73M
30 days until earnings call
NTLA
Price
$20.54
Change
+$0.58 (+2.91%)
Updated
Oct 6 closing price
Capitalization
2.2B
30 days until earnings call
Interact to see
Advertisement

IMUX vs NTLA

Header iconIMUX vs NTLA Comparison
Open Charts IMUX vs NTLABanner chart's image
Immunic
Price$0.94
Change-$0.04 (-4.08%)
Volume$2.04M
Capitalization92.73M
Intellia Therapeutics
Price$20.54
Change+$0.58 (+2.91%)
Volume$4.67M
Capitalization2.2B
IMUX vs NTLA Comparison Chart in %
IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMUX vs. NTLA commentary
Oct 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMUX is a Buy and NTLA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 07, 2025
Stock price -- (IMUX: $0.94 vs. NTLA: $20.54)
Brand notoriety: IMUX and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMUX: 146% vs. NTLA: 85%
Market capitalization -- IMUX: $92.73M vs. NTLA: $2.2B
IMUX [@Biotechnology] is valued at $92.73M. NTLA’s [@Biotechnology] market capitalization is $2.2B. The market cap for tickers in the [@Biotechnology] industry ranges from $103.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMUX’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • IMUX’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both IMUX and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMUX’s TA Score shows that 6 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).

  • IMUX’s TA Score: 6 bullish, 3 bearish.
  • NTLA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, IMUX is a better buy in the short-term than NTLA.

Price Growth

IMUX (@Biotechnology) experienced а +0.56% price change this week, while NTLA (@Biotechnology) price change was +21.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.91%. For the same industry, the average monthly price growth was +14.77%, and the average quarterly price growth was +84.62%.

Reported Earning Dates

IMUX is expected to report earnings on Nov 06, 2025.

NTLA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+6.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($2.21B) has a higher market cap than IMUX($92.7M). NTLA YTD gains are higher at: 76.158 vs. IMUX (-6.000). IMUX has higher annual earnings (EBITDA): -105.1M vs. NTLA (-501.87M). NTLA has more cash in the bank: 460M vs. IMUX (55.3M). IMUX has less debt than NTLA: IMUX (979K) vs NTLA (103M). NTLA has higher revenues than IMUX: NTLA (52.9M) vs IMUX (0).
IMUXNTLAIMUX / NTLA
Capitalization92.7M2.21B4%
EBITDA-105.1M-501.87M21%
Gain YTD-6.00076.158-8%
P/E RatioN/AN/A-
Revenue052.9M-
Total Cash55.3M460M12%
Total Debt979K103M1%
FUNDAMENTALS RATINGS
IMUX vs NTLA: Fundamental Ratings
IMUX
NTLA
OUTLOOK RATING
1..100
1012
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
33
Fair valued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4735
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMUX's Valuation (25) in the Pharmaceuticals Major industry is in the same range as NTLA (33) in the Biotechnology industry. This means that IMUX’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as IMUX (100) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to IMUX’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as IMUX (100) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to IMUX’s over the last 12 months.

NTLA's Price Growth Rating (35) in the Biotechnology industry is in the same range as IMUX (47) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to IMUX’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IMUX (100) in the Pharmaceuticals Major industry. This means that NTLA’s stock grew similarly to IMUX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMUXNTLA
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LIESX22.22N/A
N/A
Franklin International Equity IS
FIATX34.44N/A
N/A
Fidelity Advisor Intl Cap App M
CSRYX42.19N/A
N/A
Columbia Select Large Cap Value Inst3
UGTIX29.68N/A
N/A
Victory Growth and Tax Strategy Ins
GDGSX31.86N/A
N/A
Sit Global Dividend Growth S

IMUX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with PLRX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMUX
1D Price
Change %
IMUX100%
-3.91%
PLRX - IMUX
36%
Loosely correlated
-1.97%
ERAS - IMUX
35%
Loosely correlated
-3.72%
ORIC - IMUX
34%
Loosely correlated
+24.60%
NTLA - IMUX
33%
Loosely correlated
+2.91%
REVB - IMUX
31%
Poorly correlated
-4.67%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+2.91%
VCYT - NTLA
69%
Closely correlated
+0.11%
BEAM - NTLA
63%
Loosely correlated
+0.54%
CRSP - NTLA
62%
Loosely correlated
+3.62%
RXRX - NTLA
55%
Loosely correlated
+0.73%
AXON - NTLA
55%
Loosely correlated
+0.85%
More